he has been employed as general counsel of alphapharm since february 2006.
24 the lundbecks should pay alphapharm's and the secretary's costs.
in this proceeding, lundbeck australia seeks a declaration that information that it provided to the secretary in respect of the registration of therapeutic goods containing the active substance escitalopram oxalate is "protected information" within the meaning of s 25a(2) of the therapeutic goods act 1989 (cth).